Biotechnology

Biotechnology Stocks Week Ahead (Dec. 22–26, 2025): BioMarin–Amicus Deal, Cytokinetics FDA Win, IPO Filings, and Drug-Price Policy Risks

Biotechnology stocks head into the Christmas-shortened trading week with fresh momentum—and plenty for investors to digest—after a dense run of catalysts between December 19 and December 21, 2025. In the span of 48 hours, the sector saw a major rare-disease

21 December 2025

Geron Stock (NASDAQ: GERN) News Today: Restructuring, Analyst Ratings, and 2026 Catalysts (Dec. 12, 2025)

Geron Corporation (NASDAQ: GERN) stock is back in focus on December 12, 2025, as investors digest a sweeping restructuring tied to the company’s commercial push for RYTELO (imetelstat) and its longer-term clinical ambitions. The headlines have been loud—one-third of the

12 December 2025

Biotechnology · Company News · Financial Analysis · Investing · NASDAQ:GERN · Stock Market

Gilead Sciences (GILD) Stock Today: Price, Fresh News and Analyst Outlook on December 8, 2025

As of Monday, December 8, 2025, Gilead Sciences, Inc. (NASDAQ: GILD) sits near the upper end of its 52‑week range, supported by strong HIV franchises, new long‑acting prevention drugs, high‑profile cancer data at ASH 2025 and a steady dividend. At

8 December 2025

Analyst Ratings · Biotech · Market Analysis · NASDAQ:GILD · Pharmaceutical Stocks · Stock News

Picard Medical (PMI) Stock Soars 82% After Artificial Heart Breakthrough: Is This Rally Sustainable?

Picard Medical, Inc. (NYSE American: PMI) just staged one of the most dramatic moves on Wall Street, with its stock surging more than 80% on December 4, 2025, after the company released new data on its next‑generation artificial heart. Investors

5 December 2025

Biotechnology · Healthcare Innovation · Investment Analysis · Medical Technology · Stock Market

Regencell Bioscience (RGC) Stock Jumps Over 20% on December 4, 2025 as DOJ Probe and Going‑Concern Warning Shadow 2025’s Wildest Rally

Regencell Bioscience Holdings Limited (NASDAQ: RGC) is back on traders’ radar. On Thursday, December 4, 2025, RGC shares surged more than 20% intraday, trading in the mid‑teens after yet another volatile session in what has arguably been 2025’s most extreme

4 December 2025

DOJ Investigation · Financial Warnings · Market Updates · NASDAQ:RGC · Regencell Bioscience · Stock Rally

Moderna (MRNA) Stock Today, November 23, 2025: Short-Seller Pressure, $1.5 Billion Loan and mRNA Pipeline Reset

Moderna Inc. (NASDAQ: MRNA) enters Sunday, November 23, 2025, as one of the most controversial and heavily shorted stocks in the S&P 500. The biotech is trading near its 52‑week low after the COVID‑vaccine boom faded, yet it’s rolling out

23 November 2025

Biotech News · Financial Updates · Investment Analysis · Pharma Industry · Stock Market

Scholar Rock (NASDAQ: SRRK) Soars on FDA Progress, $200M ATM and Q3 2025 Earnings – November 14, 2025 Update

Scholar Rock Holding Corporation (NASDAQ: SRRK) is back in the spotlight as its stock jumps more than 25% on the day after a pivotal FDA meeting, fresh Q3 2025 financial results, and the launch of a new $200 million at-the-market

14 November 2025

Biotechnology · Earnings Reports · FDA Updates · NASDAQ:SRRK · NYSE:NVO · Pharmaceutical Industry · Stock Market

Galecto (GLTO) Soars on Damora Therapeutics Acquisition and $285M Financing: IND in 2026, Proof‑of‑Concept in 2027

Galecto, Inc. (NASDAQ: GLTO) said this morning it completed the acquisition of Damora Therapeutics and closed a $284.9 million oversubscribed private placement, a one‑two punch that instantly refocuses the company on mutant calreticulin (mutCALR) therapies for myeloproliferative neoplasms (MPNs) and

10 November 2025

Biotech News · Clinical Trials · Investment Updates · Mergers and Acquisitions · NASDAQ:GLTO · Pharmaceutical Industry

‘Yeast Survives Mars’ & ESA’s ‘Protein Out of Thin Air’: How Biology Is Rewriting the Mars Menu — and What It Means for Investors

Key facts (updated Nov 5, 2025): The story: Biology is moving from thought experiment to flight plan Europe’s HOBI‑WAN pilot (Hydrogen‑Oxidizing Bacteria in Weightlessness As a source of Nutrition) is ESA’s clearest sign yet that microbial food production will be

5 November 2025

Biotechnology · Investment Trends · Mars Research · Space Exploration · Sustainable Food

UniQure’s Roller-Coaster: Gene Therapy Breakthrough, FDA Setback, and What’s Next for QURE Stock

UniQure Stock Plunges 50% on FDA Shocker – What’s Next for QURE’s Gene Therapy Ambitions?

4 November 2025

Biotech · FDA News · Gene Therapy · NASDAQ:QURE · Pharma Industry · Stock Market

Off-the-Shelf CAR-T Triumph: Caribou’s Breakthrough Results Spark Stock Surge

Caribou’s Game-Changing CAR-T Results Caribou Biosciences – a clinical-stage biotech focusing on genome-edited cell therapies – stunned the biotech world with new data on November 3, 2025, showcasing that its off-the-shelf CAR-T cell treatments can achieve remission rates on par

3 November 2025

Biotechnology · Business News · Cancer Treatment · Medical Innovation · NASDAQ:CRBU · Stock Market

Illumina Stock Surges on Genomics Breakthroughs – What’s Next for ILMN?

Illumina Stock Rockets 20%+ After Blowout Quarter – What’s Next for ILMN?

Stock Price & Recent Performance Illumina’s stock has whipsawed in late 2025. After drifting near its 52-week lows (~$69 in late 2024), it ticked up to the mid-$90s by mid-October 2025. Following the Oct. 30 earnings report, ILMN exploded higher:

1 November 2025

Biotechnology · Earnings Reports · Financial News · Investing · Stock Market